Event News & Resources
Neuro-Bio’s invitation to visit Oxford City College for their “Advisory Board and Laboratory Showcase” – Thursday 8th May
Our CEO & Founder Baroness Susan Greenfield and Project Development Manager Bethany Watkinson have been invited by Activate Learning and Daniel Nield to visit Oxford City College for their "Advisory Board and Laboratory Showcase" on Thursday 8th May. The purpose...
First Impressions: James Barratt
James is studying for a BSc in Pharmacology at Nottingham Trent University and has joined us for a year in industry. Here's his first impressions after being with Neuro-Bio since the end of September: "Having now completed 5 weeks as an intern with Neuro-Bio its...
Neuro-Bio Continues to be Operational
Following the Government announcement on Saturday 31st October, confirming a nationwide Lockdown as of Thursday 5th November for 4 weeks, Neuro-Bio are pleased to report that since we are not a public-facing company, we will be able to resume business as usual, whilst...
Professor Paul Herrling Appointed NED to the Board
We are delighted to report Professor Herrling is now officially appointed as NED to the Board. This position had become vacated by Mr Nick Stephens who has now been invited by the Board to take over as Chair. Prof Herrling, Ph.D. was the head of corporate research at...
Mr Nick Stephens Appointed Chairman of the Board
Mr Nick Stephens first joined Neuro-Bio in Summer 2019 as a Non Executive Director (NED) to the Board, and therefore is very familiar with all aspects of the company from our scientific approach, through to our individual team members. However, following Dr Edward...
Healthy Ageing Birax UK-Israel Webinar, 14 October 2020
The goal of this Conference is to balance molecular advances with translational and clinical research, incorporating social, economic, environmental, and ethical aspects that are critical for the aged. By integrating the multiple aspects of ageing in a single...
Closure of Latest Funding Round
We are delighted that, despite the Covid-19 crisis and lab lockdown, we have been able to raise over £1.3m mezzanine B2 funding for the continuation of our pioneering research on Alzheimer’s disease. We are very grateful to our existing investors for their continued...